Moreover, when considering the administration of antibody-based immunotherapies, including hyperimmunoglobulin, CP, and monoclonal antibody therapies to COVID-19 patients, it is recommended to administer them as early as possible to cause a therapeutic effect. Here, CP is linked to COVID-19.